Sartorius Stedim Biotech: Information on Document Availability
October 24 2016 - 1:25AM
Business Wire
Regulatory News:
The Investor Relations news on the nine-month figures for 2016
of Sartorius Stedim Biotech (Paris:DIM) is now available at:
http://www.sartorius-france.fr/en/company/investor-relations/sartorius-stedim-biotech-sa/
It contains the following information:
- Business development for the period of January to September
2016 as well as the 2016 full-year forecast
- Consolidated financial statements for the period ended
September 30, 2016
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of
products and services that enable the biopharmaceutical industry to
develop and manufacture drugs safely and efficiently. As a total
solutions provider, Sartorius Stedim Biotech offers a portfolio
covering nearly all steps of biopharmaceutical manufacture. The
company focuses on single-use technologies and value-added services
to meet the rapidly changing technology requirements of the
industry it serves. Headquartered in Aubagne, France, Sartorius
Stedim Biotech is quoted on the Eurolist of Euronext Paris. With
its own manufacturing and R&D sites in Europe, North America
and Asia and a global network of sales companies, Sartorius Stedim
Biotech has a global reach. The company employs approx. 4,200
people, and in 2015 earned sales revenue of 884.3 million
euros.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161023005053/en/
Sartorius Stedim BiotechSvenja Schildknecht,
+49(0)551.308.3232Manager Investor
Relationssvenja.schildknecht@sartorius.com
WisdomTree International... (AMEX:DIM)
Historical Stock Chart
From Sep 2024 to Oct 2024
WisdomTree International... (AMEX:DIM)
Historical Stock Chart
From Oct 2023 to Oct 2024
